Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C

K. Ura, Norihiro Furusyo, Eiichi Ogawa, T. Hayashi, H. Mukae, motohiro shimizu, Kazuhiro Toyoda, Murata Masayuki, J. Hayashi

研究成果: ジャーナルへの寄稿記事

21 引用 (Scopus)

抄録

Background The Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA+-M2BP) is a new liver fibrosis glycobiomarker with unique fibrosis-related glyco-alteration. WFA+-M2BP is also a useful surrogate marker for the risk of developing hepatocellular carcinoma and for the liver functional reserve. Aim To evaluate the diagnostic ability of WFA+-M2BP for liver fibrosis in the clinical setting and the clinical utility of WFA+-M2BP for predicting the efficacy of direct-acting anti-viral (DAA) treatment for chronic hepatitis C patients. Methods The study included 159 genotype 1 hepatitis C patients who received DAA-based treatment (telaprevir or simeprevir) combined with pegylated-interferon alpha plus ribavirin (108 telaprevir- and 51 simeprevir-based triple treatment). The relation between baseline serum WFA+-M2BP and treatment efficacy was evaluated. Results The serum WFA+-M2BP level significantly increased with the progress of liver fibrosis. Area under the receiver operating characteristic curve analysis identified 2.17 as the cut-off index (COI) for WFA+-M2BP for diagnosing advanced fibrosis. The sustained virological response (SVR) rate was significantly, negatively correlated with the serum WFA+-M2BP level. Multiple logistic regression analysis found a low serum WFA+-M2BP level (<2.17 COI) to be independently associated with SVR (odds ratio, 4.35, P = 0.027). Even for prior nonresponders and patients with the interleukin-28B minor allele or histological advanced fibrosis, treatment outcome was favourable for patients with a low serum WFA+-M2BP level. Conclusion Serum WFA+-M2BP is a non-invasive liver fibrosis marker useful for predicting the efficacy of DAA-based triple therapy for chronic hepatitis C patients.

元の言語英語
ページ(範囲)114-124
ページ数11
ジャーナルAlimentary Pharmacology and Therapeutics
43
発行部数1
DOI
出版物ステータス出版済み - 1 1 2016

Fingerprint

Chronic Hepatitis C
Liver Cirrhosis
Serum
Fibrosis
Therapeutics
Ribavirin
Interleukins
Hepatitis C
Interferon-alpha
ROC Curve
Hepatocellular Carcinoma
Biomarkers
Logistic Models
Alleles
Odds Ratio
Genotype
Regression Analysis
Liver

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

これを引用

Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. / Ura, K.; Furusyo, Norihiro; Ogawa, Eiichi; Hayashi, T.; Mukae, H.; shimizu, motohiro; Toyoda, Kazuhiro; Masayuki, Murata; Hayashi, J.

:: Alimentary Pharmacology and Therapeutics, 巻 43, 番号 1, 01.01.2016, p. 114-124.

研究成果: ジャーナルへの寄稿記事

@article{2bc4b4c93c6a445f8188499f415a81a0,
title = "Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C",
abstract = "Background The Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA+-M2BP) is a new liver fibrosis glycobiomarker with unique fibrosis-related glyco-alteration. WFA+-M2BP is also a useful surrogate marker for the risk of developing hepatocellular carcinoma and for the liver functional reserve. Aim To evaluate the diagnostic ability of WFA+-M2BP for liver fibrosis in the clinical setting and the clinical utility of WFA+-M2BP for predicting the efficacy of direct-acting anti-viral (DAA) treatment for chronic hepatitis C patients. Methods The study included 159 genotype 1 hepatitis C patients who received DAA-based treatment (telaprevir or simeprevir) combined with pegylated-interferon alpha plus ribavirin (108 telaprevir- and 51 simeprevir-based triple treatment). The relation between baseline serum WFA+-M2BP and treatment efficacy was evaluated. Results The serum WFA+-M2BP level significantly increased with the progress of liver fibrosis. Area under the receiver operating characteristic curve analysis identified 2.17 as the cut-off index (COI) for WFA+-M2BP for diagnosing advanced fibrosis. The sustained virological response (SVR) rate was significantly, negatively correlated with the serum WFA+-M2BP level. Multiple logistic regression analysis found a low serum WFA+-M2BP level (<2.17 COI) to be independently associated with SVR (odds ratio, 4.35, P = 0.027). Even for prior nonresponders and patients with the interleukin-28B minor allele or histological advanced fibrosis, treatment outcome was favourable for patients with a low serum WFA+-M2BP level. Conclusion Serum WFA+-M2BP is a non-invasive liver fibrosis marker useful for predicting the efficacy of DAA-based triple therapy for chronic hepatitis C patients.",
author = "K. Ura and Norihiro Furusyo and Eiichi Ogawa and T. Hayashi and H. Mukae and motohiro shimizu and Kazuhiro Toyoda and Murata Masayuki and J. Hayashi",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/apt.13431",
language = "English",
volume = "43",
pages = "114--124",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C

AU - Ura, K.

AU - Furusyo, Norihiro

AU - Ogawa, Eiichi

AU - Hayashi, T.

AU - Mukae, H.

AU - shimizu, motohiro

AU - Toyoda, Kazuhiro

AU - Masayuki, Murata

AU - Hayashi, J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background The Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA+-M2BP) is a new liver fibrosis glycobiomarker with unique fibrosis-related glyco-alteration. WFA+-M2BP is also a useful surrogate marker for the risk of developing hepatocellular carcinoma and for the liver functional reserve. Aim To evaluate the diagnostic ability of WFA+-M2BP for liver fibrosis in the clinical setting and the clinical utility of WFA+-M2BP for predicting the efficacy of direct-acting anti-viral (DAA) treatment for chronic hepatitis C patients. Methods The study included 159 genotype 1 hepatitis C patients who received DAA-based treatment (telaprevir or simeprevir) combined with pegylated-interferon alpha plus ribavirin (108 telaprevir- and 51 simeprevir-based triple treatment). The relation between baseline serum WFA+-M2BP and treatment efficacy was evaluated. Results The serum WFA+-M2BP level significantly increased with the progress of liver fibrosis. Area under the receiver operating characteristic curve analysis identified 2.17 as the cut-off index (COI) for WFA+-M2BP for diagnosing advanced fibrosis. The sustained virological response (SVR) rate was significantly, negatively correlated with the serum WFA+-M2BP level. Multiple logistic regression analysis found a low serum WFA+-M2BP level (<2.17 COI) to be independently associated with SVR (odds ratio, 4.35, P = 0.027). Even for prior nonresponders and patients with the interleukin-28B minor allele or histological advanced fibrosis, treatment outcome was favourable for patients with a low serum WFA+-M2BP level. Conclusion Serum WFA+-M2BP is a non-invasive liver fibrosis marker useful for predicting the efficacy of DAA-based triple therapy for chronic hepatitis C patients.

AB - Background The Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA+-M2BP) is a new liver fibrosis glycobiomarker with unique fibrosis-related glyco-alteration. WFA+-M2BP is also a useful surrogate marker for the risk of developing hepatocellular carcinoma and for the liver functional reserve. Aim To evaluate the diagnostic ability of WFA+-M2BP for liver fibrosis in the clinical setting and the clinical utility of WFA+-M2BP for predicting the efficacy of direct-acting anti-viral (DAA) treatment for chronic hepatitis C patients. Methods The study included 159 genotype 1 hepatitis C patients who received DAA-based treatment (telaprevir or simeprevir) combined with pegylated-interferon alpha plus ribavirin (108 telaprevir- and 51 simeprevir-based triple treatment). The relation between baseline serum WFA+-M2BP and treatment efficacy was evaluated. Results The serum WFA+-M2BP level significantly increased with the progress of liver fibrosis. Area under the receiver operating characteristic curve analysis identified 2.17 as the cut-off index (COI) for WFA+-M2BP for diagnosing advanced fibrosis. The sustained virological response (SVR) rate was significantly, negatively correlated with the serum WFA+-M2BP level. Multiple logistic regression analysis found a low serum WFA+-M2BP level (<2.17 COI) to be independently associated with SVR (odds ratio, 4.35, P = 0.027). Even for prior nonresponders and patients with the interleukin-28B minor allele or histological advanced fibrosis, treatment outcome was favourable for patients with a low serum WFA+-M2BP level. Conclusion Serum WFA+-M2BP is a non-invasive liver fibrosis marker useful for predicting the efficacy of DAA-based triple therapy for chronic hepatitis C patients.

UR - http://www.scopus.com/inward/record.url?scp=84951907013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951907013&partnerID=8YFLogxK

U2 - 10.1111/apt.13431

DO - 10.1111/apt.13431

M3 - Article

VL - 43

SP - 114

EP - 124

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 1

ER -